BMRN BioMarin Pharmaceutical Inc.

93.11
-0.78  -1%
Previous Close 93.89
Open 92.64
Price To Book 5.69
Market Cap 16579362690
Shares 178,062,106
Volume 952,097
Short Ratio
Av. Daily Volume 1,108,378

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 2Q 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 3 top-line data due end of 2019.
Vosoritide
Achondroplasia
Approval announced May 24, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
Phase 1/2 update May 22, 2018 noted 97% decrease in bleeding rate. Further data due May 2019 with BLA filing due 2H 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 1/2 dosing has commenced - noted May 15, 2018.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 2 commencement of dosing announced June 14, 2018.
Vosoritide
Achondroplasia - young children

Latest News

  1. Argentiere Capital’s Returns, AUM and Holdings
  2. Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
  3. Why Neurocrine Biosciences Stock Is Plummeting Today
  4. Is BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) CEO Paid Enough Relative To Peers?
  5. See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
  6. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019
  7. Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN)
  8. Analysis: Positioning to Benefit within BioMarin Pharmaceutical, Ritchie Bros. Auctioneers, ADTRAN, Aspen Technology, AMC Entertainment, and Halliburton — Research Highlights Growth, Revenue, and Consolidated Results
  9. Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
  10. BioMarin Promotes Amy Wireman to Group Vice President, Human Resources
  11. BioMarin to Participate in Citi's 13th Annual Biotech Conference on December 5 in New York City
  12. How BioMarin Pharmaceutical’s Product Portfolio Has Performed
  13. Bayer will shift hemophilia drug work to Berkeley, but won't add jobs
  14. How BioMarin Pharmaceutical’s Financials Look in November
  15. Why Catalyst Pharmaceuticals Stock Is Sinking Today
  16. Wall Street Analysts Are Mostly Positive on BioMarin
  17. Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma
  18. U.S. FDA approves Catalyst Pharma's rare disease drug